subject
fortyeight
healthi
adult
volunt
age
year
serum
neutral
antibodi
titer
recruit
studi
approv
independ
institut
review
board
volunt
gave
written
inform
consent
particip
individu
condit
like
affect
suscept
cold
sever
durat
cold
symptom
exclud
studi
individu
receiv
medic
known
affect
rhinorrhea
cough
nasal
congest
within
day
week
cromolyn
sodium
longact
antihistamin
studi
initi
exclud
pregnant
breastfeed
women
particip
report
sensit
ingredi
studi
product
also
exclud
particip
receiv
financi
compens
treatment
one
group
particip
receiv
formul
contain
press
juic
aboveground
plant
part
e
purpurea
place
alcohol
base
echinaguard
anoth
group
receiv
match
placebo
activ
medic
placebo
ident
appear
tast
smell
packag
ident
bottl
experiment
design
particip
random
receiv
either
echinacea
placebo
ml
time
per
day
everi
h
day
day
particip
return
earli
morn
viru
inocul
day
inocul
administ
intranas
via
pipett
inocula
provid
min
apart
total
dose
ml
per
nostril
particip
supin
posit
particip
ask
blow
nose
min
viral
challeng
viru
origin
clinic
isol
kindli
provid
use
viru
pool
test
safeti
total
viru
inoculum
equival
per
volunt
begin
h
viru
inocul
ie
continu
particip
isol
individu
hotel
room
assess
hotel
stay
particip
continu
treatment
echinacea
placebo
previous
instruct
particip
complet
treatment
home
identif
infect
serolog
assess
serum
neutral
antibodi
titer
made
viru
inocul
describ
elsewher
specimen
viral
cultur
obtain
nasal
lavag
subject
hotel
stay
identifi
presenc
rhinoviru
infect
defin
least
increas
neutral
antibodi
titer
andor
recoveri
rhinoviru
viral
cultur
clinic
measur
ill
occurr
sever
symptom
record
time
daili
diari
card
begin
day
viru
inocul
continu
use
sever
rate
scale
absent
mild
moder
sever
symptom
assess
rhinorrhea
congest
sneez
cough
sore
throat
headach
malais
chilli
thereaft
symptom
assess
per
day
complet
studi
maximum
score
daili
assess
individu
symptom
rhinoviru
inocul
ad
give
total
symptom
score
clinic
presenc
defin
total
symptom
score
follow
success
day
rhinorrhea
posit
respons
queri
whether
subject
felt
develop
cold
sinc
viru
inocul
method
symptom
score
diagnos
ill
modif
method
jackson
et
al
gwaltney
et
al
describ
elsewher
data
analysi
demograph
paramet
test
treatment
group
differ
student
test
analysi
appropri
ninetyf
percent
ci
construct
proport
treatment
group
met
criteria
infect
well
differ
proport
treatment
group
ci
differ
base
normal
approxim
binomi
distribut
treatment
proport
also
compar
use
fisher
exact
test
analysi
studi
design
first
stage
adapt
design
base
methodolog
describ
bauer
primari
end
point
determin
priori
develop
cold
defin
separ
laboratori
infect
clinic
ill
subject
complet
studi
clinic
virolog
end
point
known
subject
adapt
interim
statist
analysi
data
perform
determin
final
sampl
size
studi
redefin
primari
efficaci
paramet
critic
p
level
reject
null
hypothesi
complet
stage
p
valu
stage
exceed
critic
level
primari
outcom
criterion
stage
could
revis
basi
outcom
show
greatest
sensit
resolv
treatment
differ
stage
power
test
stage
comput
basi
sampl
size
subject
per
treatment
group
outcom
rate
observ
stage
level
otherwis
studi
termin
stage
infect
use
primari
end
point
power
stage
estim
clinic
criterion
ill
use
power
stage
estim
view
primari
import
assign
studi
sponsor
infect
criterion
sponsor
decid
termin
studi
stage
basi
estim
areaunderthecurv
valu
total
symptom
score
show
mean
symptom
score
echinacea
placebo
pool
sd
sampl
size
subject
per
treatment
group
would
requir
provid
power
detect
statist
signific
differ
level
signific
particip
total
volunt
treatment
group
enrol
random
receiv
studi
drug
particip
complet
studi
two
particip
placebo
group
exclud
efficaci
analysi
one
particip
entri
moder
sneez
daili
diari
viru
inocul
particip
posit
serum
neutral
antibodi
titer
inocul
signific
differ
echinacea
placebo
group
regard
sex
vs
male
subject
mean
age
vs
year
assess
infect
fourfold
greater
increas
serum
neutral
antibodi
titer
occur
echinacea
recipi
placebo
recipi
rhinoviru
recov
volunt
echinacea
placebo
group
respect
frequenc
viru
recoveri
group
cultur
posit
rhinoviru
overal
proport
particip
demonstr
laboratori
evid
infect
echinacea
recipi
ci
placebo
recipi
ci
assess
ill
cold
develop
echinacea
recipi
ci
placebo
recipi
ci
p
fisher
exact
test
differ
rate
rang
total
symptom
score
recipi
echinacea
placebo
recipi
similarli
daili
symptom
score
tend
lower
echinacea
recipi
day
inocul
placebo
recipi
differ
signific
figur
individu
symptom
score
significantli
differ
treatment
group
tabl
infect
echinacea
recipi
develop
cold
compar
placebo
recipi
p
fisher
exact
test
toler
six
particip
placebo
group
echinacea
group
report
total
advers
event
treatmentlimit
advers
event
advers
event
report
subject
treat
echinacea
sleepless
sever
oral
aphthou
ulcer
resolv
spontan
receiv
treatment
event
evalu
improb
relat
studi
treatment
e
purpurea
one
commonli
use
herbal
remedi
unit
state
often
ingest
prevent
amelior
cours
common
cold
control
trial
use
challeng
model
studi
effect
press
juic
aboveground
plant
part
e
purpurea
administ
day
day
inocul
rhinoviru
cold
result
studi
suggest
echinacea
effect
prevent
rhinoviru
infect
defin
laboratori
criteria
among
infect
receiv
echinacea
trend
toward
reduct
number
clinic
cold
compar
infect
receiv
placebo
vs
p
number
studi
use
vari
studi
design
varieti
plant
part
root
aboveground
compon
differ
speci
echinacea
alon
combin
herb
report
variou
mostli
prevent
natur
cold
forth
beuscher
studi
effect
tablet
liquid
product
contain
root
e
angustifolia
e
pallida
extract
selfreport
incid
sever
natur
cold
tablet
recipi
fewer
nasal
symptom
placebo
recipi
outcom
similar
schmidt
et
al
studi
prepar
e
angustifolia
herb
root
extract
administ
colleg
student
week
prevent
upper
respiratori
tract
infect
flulik
ill
report
reduct
ill
achiev
statist
signific
studi
conduct
melchart
et
al
compar
regimen
extract
root
e
purpurea
e
angustifolia
placebo
prevent
cold
volunt
observ
signific
differ
rate
infect
time
first
infect
grimm
muller
report
trial
press
juic
aboveground
part
e
purpurea
ingest
week
prevent
natur
cold
signific
differ
incid
sever
durat
cold
echinacea
match
placebo
subject
schoneberg
previous
report
result
trial
previous
publish
studi
evalu
echinacea
experiment
cold
turner
et
al
administ
echinacea
day
day
challeng
observ
benefit
numer
studi
evalu
echinacea
treatment
establish
cold
vari
definit
respiratori
ill
end
point
method
data
collect
differ
time
initi
treatment
cours
ill
make
comparison
studi
difficult
furthermor
prepar
echinacea
use
variou
studi
may
significantli
differ
amount
activ
ingredi
clinic
efficaci
although
modest
case
report
mani
treatment
studi
suggest
echinacea
associ
greater
benefit
treat
establish
cold
prevent
infect
recent
publish
control
trial
barrett
et
al
report
benefici
effect
mixtur
unrefin
e
purpurea
herb
root
e
angustifolia
root
treatment
natur
cold
studi
observ
trend
toward
reduct
total
symptom
score
frequenc
ill
meet
definit
cold
echinacea
recipi
one
explan
trend
toward
improv
clinic
ill
without
effect
rate
infect
observ
may
result
benefici
effect
echinacea
associ
treatment
establish
infect
rather
prevent
therapi
continu
day
viru
inocul
time
subject
symptomat
use
experiment
cold
model
may
allow
earli
symptom
assess
accur
trial
involv
natur
cold
studi
unfortun
compromis
small
sampl
size
result
consist
previous
report
data
regard
lack
efficaci
echinacea
prevent
natur
experiment
cold
investig
echinacea
treatment
experiment
rhinoviru
infect
larger
number
subject
specif
standard
prepar
echinacea
known
potenc
clarifi
efficaci
echinacea
treatment
cold
